Idea principal
A joint expert advisory says GLP-1 drugs cut body weight by 5% to 18% in trials, less in real-world analyses, and that nutrition and lifestyle care is needed to handle side effects, muscle and bone loss, and weight regain. It is an expert consensus built from a literature appraisal, not a trial, so its priorities are recommendations rather than tested results.
Study design
Artículo de investigación
Reading basis
Published abstract
Reading focus
Design & applicability
Esta explicación editorial está disponible en inglés, chino simplificado y chino tradicional. Esta interfaz muestra la lectura en inglés.
Pregunta de investigación
GLP-1 receptor agonists and related combination drugs are changing obesity treatment, but side effects, nutrient gaps, muscle loss, poor long-term adherence and cost can limit their benefit. The authors, a group of four US professional societies, set out to name practical nutrition and lifestyle priorities for clinicians who treat patients with these drugs.
Población y método
Expert group from several clinical and research disciplines, convened by the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association and The Obesity Society. They appraised the scientific literature, informed by expert knowledge and clinical experience, to summarise topics, priorities and emerging directions. The abstract does not describe a systematic search or any scoring of evidence quality.
Resultados
The authors’ reported results. Read each estimate with its population and uncertainty.
- 1GLP-1s lowered body weight by 5% to 18% in trials, with modestly lower effects in real-world analyses, alongside multiple demonstrated clinical benefits.
- 2Key problems: gastrointestinal side effects, nutritional deficiencies from eating less, muscle and bone loss, low long-term adherence with weight regain, and high cost.
- 3Guidelines already recommend multicomponent nutritional and behavioural therapy for adults with obesity, but it is not widely combined with GLP-1s.
- 4Priorities include screening before starting (eating habits, emotional triggers, disordered eating, muscle strength and body composition, social needs, activity, sleep and stress), managing side effects, preventing deficiencies, and preserving muscle and bone through resistance training and suitable diet.
- 5Support options include group visits, dietitian counselling, telehealth and digital platforms, and Food is Medicine programmes; open questions include maintaining weight after stopping the drug.
Límites e incertidumbre
- 1It is an expert advisory, so the priorities reflect the authors' judgement and appraisal of the literature rather than a systematic review or new data.
- 2The abstract gives no per-recommendation strength of evidence, and several items are listed as areas still needing study.
- 3Weight-loss figures come from trials and may not match what an individual experiences.
Relevancia práctica
If you use or are considering a GLP-1 drug, this suggests asking your clinician about protein and overall diet, resistance training, and screening for deficiencies, rather than relying on the drug alone. Whether to start, change or stop a medication is a decision for you and your clinician.
Tus datos
Useful records while on treatment include body weight trends, food logs, strength-training sessions, daily steps and sleep duration. Weigh at the same time of day on the same scale and look at multi-week trends; weight alone cannot show muscle loss, so discuss body composition checks with your care team.
Cómo interpretar la evidencia
The index does not establish a precise design. Read the methods before making causal claims; check population, comparator, outcomes and uncertainty in the source.
Resumen estructurado de los autores English
El resumen original en inglés se reproduce con atribución bajo la licencia indicada. Es una fuente, no una interpretación de MoveVitals. El análisis preparado figura arriba; verifica los resultados importantes en la fuente.
Background
Glucagon-like peptide 1 receptor agonists and combination medications (hereafter collectively referred to as GLP-1s) are shifting the treatment landscape for obesity. However, real-world challenges and limited clinician and public knowledge on nutritional and lifestyle interventions can limit GLP-1 efficacy, equitable results, and cost-effectiveness.
Objectives
We aimed to identify pragmatic priorities for nutrition and other lifestyle interventions relevant to GLP-1 treatment of obesity for the practicing clinician.
Methods
An expert group comprising multiple clinical and research disciplines appraised the scientific literature, informed by expert knowledge and clinical experience, to identify and summarize relevant topics, priorities, and emerging directions.
Results
GLP-1s reduce body weight by 5% to 18% in trials, with modestly lower effects in real-world analyses, and multiple demonstrated clinical benefits. Challenges include side effects, especially gastrointestinal; nutritional deficiencies due to calorie reduction; muscle and bone loss; low long-term adherence with subsequent weight regain; and high costs with resulting low cost-effectiveness. Numerous practice guidelines recommend multicomponent, evidence-based nutritional and behavioral therapy for adults with obesity, but use of such therapies with GLP-1s is not widespread. Priorities to address this include: (a) patient-centered initiation of GLP-1s, including goals for weight reduction and health; (b) baseline screening, including usual dietary habits, emotional triggers, disordered eating, and relevant medical conditions; (c) comprehensive exam including muscle strength, function, and body composition assessment; (d) social determinants of health screening; (e) and lifestyle assessment including aerobic activity, strength training, sleep, mental stress, substance use, and social connections. During GLP-1 use, nutritional and medical management of gastrointestinal side effects is critical, as is navigating altered dietary preferences and intakes, preventing nutrient deficiencies, preserving muscle and bone mass through resistance training and appropriate diet, and complementary lifestyle interventions. Supportive strategies include group-based visits, registered dietitian nutritionist counseling, telehealth and digital platforms, and Food is Medicine interventions. Drug access, food and nutrition insecurity, and nutrition and culinary knowledge influence equitable obesity management with GLP-1s. Emerging areas for more study include dietary modulation of endogenous GLP-1, strategies to improve compliance, nutritional priorities for weight maintenance post-cessation, combination or staged intensive lifestyle management, and diagnostic criteria for clinical obesity.
Conclusions
Evidence-based nutritional and lifestyle strategies play a pivotal role to address key challenges around GLP-1 treatment of obesity, making clinicians more effective in advancing their patients' health.
Fuentes y atribución
Nutritional priorities to support GLP-1 therapy for obesity: A joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society.
Mozaffarian D, Agarwal M, Aggarwal M, Alexander L, Apovian CM, Bindlish S, Bonnet J, Butsch WS, Christensen S, Gianos E, Gulati M, Gupta A, Horn D, Kane RM, Saluja J, Sannidhi D, Stanford FC, Callahan EA.
Obesity (Silver Spring, Md.) · 2025-05-30
DOI: 10.1002/oby.24336 ↗PubMed · 40445127 ↗Europe PMC · Licencia registrada: cc by ↗Abstract © the original authors, reproduced under the recorded open licence. Translations support reading; use the English record to check terminology and numerical results. Our methodological interpretation is separate from the authors’ conclusions.
Interpretación editorial de MoveVitals · contenido educativo · sin revisión clínica individual registrada
Fuentes verificadas 2026-11-01
Guías prácticas
Leer en contexto
Early time-restricted eating linked to more weight loss and lower insulin than late eating
Pooling 41 randomised trials (2287 participants, median intervention 8 weeks), time-restricted eating was associated with 2.15 kg lower body weight than usual diets (95% CI -2.56 to -1.74), and eating early beat eating late by 1.15 kg (95% CI -1.86 to -0.45). Most trials were short, only 6 study arms tested early eating, and the outcomes were body and blood measures, not heart attacks or deaths.
BMJ Medicine
An 8 a.m. to 4 p.m. eating window added to calorie cutting gave no clear extra weight loss
Among 139 patients with obesity on a calorie-restricted diet, adding an eating window of 8:00 a.m. to 4:00 p.m. led to a mean 12-month weight change of -8.0 kg, versus -6.3 kg with calorie restriction alone. The net difference of -1.8 kg (95% CI -4.0 to 0.4; P = 0.11) was not statistically significant, and the interval cannot rule out either a real benefit or none.
The New England Journal of Medicine
In a 20-person ward trial, an ultra-processed menu led to more eating and weight gain
In 20 adults living in a hospital research unit for 28 days, an ultra-processed menu led them to eat 508 kcal/day more (± 106 SE, P = 0.0001) and gain 0.9 kg, while a menu of unprocessed foods led to a 0.9 kg loss, each over 2 weeks and with eating left to appetite. The study was small, short and fully provisioned, so it cannot show what happens in daily life or which feature of the foods drove the extra eating.
Cell Metabolism
Mediterranean diet with olive oil or nuts linked to fewer heart events (corrected trial)
Among 7447 Spanish adults aged 55 to 80 at high cardiovascular risk, those assigned to a Mediterranean diet with extra-virgin olive oil (HR 0.69, 95% CI 0.53 to 0.91) or with nuts (HR 0.72, 0.54 to 0.95) had fewer major cardiovascular events than those told to cut dietary fat. The trial had randomisation errors, which is why the 2013 report was withdrawn and the estimates recalculated, so treat this as strong but imperfect evidence.
The New England Journal of Medicine

